Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US98978V1035
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG0039320N9
ZTS
Zoetis Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—Specialty & Generic · THEMEFOLIO: $BIRD
NAME
Zoetis Inc
ISIN
US98978V1035
TICKER
ZTS
MIC
XNYS
REUTERS
ZTS.N
BLOOMBERG
ZTS US
Mi., 29.10.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 30.10.2025 und ex Dividende/Zinsen am 31.10.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 30.10.2025 and its ex-dividend/interest day on 31.10.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 29.10.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Built on a decade of science and research, Lenivia is a new antibody therapy with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced in...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Fr., 10.10.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP’s positive opinion, th...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world’s leading animal health com...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 23.09.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call. Investors an...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Fr., 12.09.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (O...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentation...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 01.07.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 05.06.2025       Zoetis
US98978V1035

Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the company’s continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis’ fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 22.05.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to t...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 21.05.2025       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world’s leading animal health compan...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 15.05.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 16.04.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 17.04.2025 und ex Dividende/Zinsen am 22.04.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 17.04.2025 and its ex-dividend/interest day on 22.04.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 16.04.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 17.04.2025 und ex Dividende/Zinsen am 22.04.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 17.04.2025 and its ex-dividend/interest day on 22.04.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 27.03.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 20.02.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET. Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET. Investors and other inter...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 14.02.2025       Zoetis
US98978V1035

Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonabl...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 13.02.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter o...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 06.02.2025       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the second quarter of 2025. The dividend will be paid on Tuesday, June 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Monday, April 21, 2025. About Zoetis As the world’s leading animal health company,...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 04.02.2025       Zoetis
US98978V1035

Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA). This supplement includes updated labeling based on post-approval experience with Librela in the U.S. since the product launched over a year ago. The company re...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 20.01.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 21.01.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 21.01.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 20.01.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 21.01.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 21.01.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
So., 19.01.2025       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 20.01.2025 und ex Dividende/Zinsen am 21.01.2025 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 20.01.2025 and its ex-dividend/interest day on 21.01.2025...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the cal...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21,...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET. Investors and other interested parties will be able to access a live...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 11.11.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS. The company reported revenue of $2.4 billion for the third quarter of 2024, an increase of 11% compared with the third quarter of 2023. On an operational1 basis, revenue for the third quart...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 30.10.2024       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 31.10.2024 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 31.10.2024...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 29.10.2024       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird cum Dividende/Zinsen gehandelt am 30.10.2024 und ex Dividende/Zinsen am 31.10.2024 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its pre-dividend/interest day on 30.10.2024 and its ex-dividend/interest day on 31.10.2024...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 10.10.2024       Zoetis
US98978V1035

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world’s leading animal health co...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 26.09.2024       Zoetis
US98978V1035

Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today’s dairy farms through the power of genetics for healthier cows. Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to innovate the dairy industry’s approach to breedi...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 19.09.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 20.08.2024       Zoetis
US98978V1035

Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET. Investors and o...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 17.07.2024       Zoetis
US98978V1035

Das Instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY wird ex Dividende/Zinsen gehandelt am 18.07.2024 The instrument ZOE US98978V1035 ZOETIS INC. CL.A DL -,01 EQUITY has its ex-dividend/interest day on 18.07.2024...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 03.06.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - June 3, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers an...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
So., 26.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 26, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers an...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
So., 19.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 18, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers an...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Fr., 17.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 17, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 16.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 16, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mi., 15.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 15, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Di., 14.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 14, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Mo., 13.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 13, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Fr., 10.05.2024       Zoetis
US98978V1035

New York, New York--(Newsfile Corp. - May 10, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zoetis and certain of its officers...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink
Do., 02.05.2024       Zoetis
US98978V1035

Radnor, Pennsylvania--(Newsfile Corp. - May 2, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Zoetis Inc. (NYSE: ZTS) ("Zoetis"). On April 12, 2024, The Wall Street Journal published an article on Zoetis reporting...
Zur Nachricht
Zoetis
Charts & Research Termsheets Terminal
Permalink